Hormonal
Newer diabetes medications, specifically GLP-1 receptor agonists (like tirzepatide) and SGLT2 inhibitors, facilitate diabetes remission through significant weight loss and glycemic control, though long-term remission data is still emerging.
Newer drugs like tirzepatide and GLP-1 agonists can achieve high remission rates (up to 81%) by combining weight loss with hormonal effects. However, they are expensive, require injections, and long-term remission data is still being gathered. They are a safer alternative to surgery for some, but not a guaranteed cure.
Recently, tirzepatide with higher potency has been developed and approved; it is a drug that exhibits dual action in both types of incretins... The drug resulted in a remission rate of 66% to 81%, depending on the drug dose over 52 weeks of use in a clinical study.
Why this rating
Based on clinical trials, but long-term durability and remission definition consistency are less clear.
Source
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Jinyoung Kim et al. · Diabetes & Metabolism Journal · 2022
DOI 10.4093/dmj.2021.0377
More from this paper
- Significant weight loss (induced by metabolic surgery, very-low-calorie diets, or intensive insulin therapy) prior to irreversible beta-cell damage can induce durable remission of type 2 diabetes, defined as HbA1c <6.5% without medication.Good
- Metabolic surgery (specifically Roux-en-Y gastric bypass) yields higher remission rates than adjustable gastric banding, independent of the amount of weight lost.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →